Inflammasomes are multiprotein complexes that signal by oligomerizing the apoptosis speck-like protein with caspase recruitment and activator domain (ASC) and are involved in multiple inflammatory, metabolic and degenerative diseases. Pharmacological targeting of specific inflammasomes with small molecules is leading to the development of novel drugs for most common diseases. The targeting of ASC oligomers will result in a pan-inflammasome treatment. In their study, Bertheloot et al (2022) developed specific anti-ASC nanobodies and showed their efficacy to disaggregate already formed ASC oligomers and to treat inflammatory diseases in animal models. This approach represents a novel biologic-based treatment for inflammasomes-initiated inflammatory diseases.

中文翻译：

---

ASC 纳米抗体可抵消炎症小体激活的后果

炎症小体是多蛋白复合物，通过将凋亡斑点样蛋白与半胱天冬酶募集和激活域 (ASC) 寡聚化来发出信号，并参与多种炎症、代谢和退行性疾病。具有小分子的特定炎症小体的药理学靶向正在导致针对大多数常见疾病的新药的开发。ASC 寡聚体的靶向将导致泛炎体治疗。在他们的研究中，Bertheloot等人(2022) 开发了特定的抗 ASC 纳米抗体，并在动物模型中展示了它们在分解已经形成的 ASC 寡聚体和治疗炎症性疾病方面的功效。这种方法代表了一种新的基于生物的治疗炎症小体引发的炎症性疾病。